Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant. (22nd July 2022)

• Record Type: Journal Article
• Authors: Huygens, Sammy; Oude Munnink, Bas; Gharbharan, Arvind; Koopmans, Marion; Rijnders, Bart
• Is Part Of: Clinical infectious diseases. Volume 76:Number 3(2023)
• Page Start: e507
• Page End: e509
• Publication Date: 2022-07-22
• Subjects: SARS-CoV-2 -- Omicron -- sotrovimab -- resistance -- immunocompromised; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac601
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.